Perfil clínico das gestantes com síndromes hipertensivas atendidas no CAIS da Mulher em Anápolis-GO

As síndromes hipertensivas na gestação são classificadas em quatro categorias: pré-eclâmpsia/eclâmpsia, hipertensão arterial crônica, hipertensão arterial crônica com pré-eclâmpsia superajuntada e hipertensão gestacional. As crises hipertensivas são caracterizadas por um aumento acentuado da pressão arterial, que pode acarretar, para a gestante e o feto, complicações graves e até levar ao óbito. Este estudo tem como objetivo descrever o perfil clínico de gestantes com síndromes hipertensivas, além de identificar a ocorrência de complicações obstétricas decorrentes. Trata-se de um estudo observacional transversal analítico. Será realizado no município de Anápolis - Goiás por meio de coleta dos dados com aplicação de questionários, em uma população de 46 gestantes, entre o período de agosto a dezembro de 2023. As características sociodemográficas avaliadas serão: faixa etária; etnia; nível de escolaridade; renda familiar; estado marital; profissão. As variáveis clínico-epidemiológicas serão: medidas da pressão arterial; número de gestações; idade gestacional; comorbidades. Espera-se relatar o perfil das gestantes com síndromes hipertensivas, bem como as complicações obstétricas relacionadas. Dessa maneira, identificar a prevalência e as variáveis clínicas mais recorrentes das pacientes avaliadas no CAIS da Mulher no município de Anápolis – GO. Portanto, com o presente estudo espera-se contribuir para o arcabouço literário do tema abordado e enfatizar que é fundamental ampliar a compreensão do fenômeno estudado, a fim de prevenir os agravos decorrentes das síndromes hipertensivas na gravidez

The PLATO Mission

International audiencePLATO (PLAnetary Transits and Oscillations of stars) is ESA's M3 mission designed to detect and characterise extrasolar planets and perform asteroseismic monitoring of a large number of stars. PLATO will detect small planets (down to <2 R_(Earth)) around bright stars (<11 mag), including terrestrial planets in the habitable zone of solar-like stars. With the complement of radial velocity observations from the ground, planets will be characterised for their radius, mass, and age with high accuracy (5 %, 10 %, 10 % for an Earth-Sun combination respectively). PLATO will provide us with a large-scale catalogue of well-characterised small planets up to intermediate orbital periods, relevant for a meaningful comparison to planet formation theories and to better understand planet evolution. It will make possible comparative exoplanetology to place our Solar System planets in a broader context. In parallel, PLATO will study (host) stars using asteroseismology, allowing us to determine the stellar properties with high accuracy, substantially enhancing our knowledge of stellar structure and evolution. The payload instrument consists of 26 cameras with 12cm aperture each. For at least four years, the mission will perform high-precision photometric measurements. Here we review the science objectives, present PLATO's target samples and fields, provide an overview of expected core science performance as well as a description of the instrument and the mission profile at the beginning of the serial production of the flight cameras. PLATO is scheduled for a launch date end 2026. This overview therefore provides a summary of the mission to the community in preparation of the upcoming operational phases

Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

Aims The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. Methods and results Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (inhospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, prehospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. Conclusion The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality